Figure S1. Zhao et al. a b c Figure. S1. VEGF does not stimulate population increase and cell cycle changes in breast cancer cells. (a) 20000 cells from.

Slides:

Advertisements

Similar presentations

Mandal CC et al Supplementary Fig. S1. Increased expression of CSF-1 in human breast cancer cells. (A) The conditioned media from normal human breast epithelial.

Advertisements

Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells

Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells

Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells

Bufalin Inhibits the Differentiation and Proliferation of Cancer Stem Cells Derived from Primary Osteosarcoma Cells through Mir-148a Cell Physiol Biochem.

Figure S1. qPCR analysis of the EMT markers ZEB2 and SNAI1 in Syndecan-1 and control siRNA transfected MDA-MB-231 and MCF-7 cells reveals no significant.

Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells

a b SUM149PT Motility Invasion C V C V

Volume 7, Issue 3, Pages (May 2014)

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Dihydromyricetin decreases the sphere formation through downregulation of Sox2 in human osteosarcoma. Dihydromyricetin decreases the sphere formation through.

Expression of FUT9 supports tumor development

The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Volume 21, Issue 10, Pages (December 2017)

Validation of St6GalNAc2 as a metastasis suppressor gene.

VEGF signals via a paracrine loop to VEGFR-2 in the glomerulus.

Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.

COX-2–PGE2 signaling is required for MSC-induced increase in ALDHhigh CSC-enriched population and tumor initiation. COX-2–PGE2 signaling is required for.

A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced cells. A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced.

Volume 39, Issue 3, Pages (September 2013)

Molecular Therapy - Nucleic Acids

Marta Vilalta, Marjan Rafat, Amato J. Giaccia, Edward E. Graves

An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation Dimitrios Iliopoulos, Heather A. Hirsch,

PERK signaling is constitutively activated upon EMT and promotes malignancy. PERK signaling is constitutively activated upon EMT and promotes malignancy.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice. Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice.

A: Chemical structure of pterosin A

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

NK Cells Fighting Cancer

CT-26 colon cancer induces the recruitment of protumor mast cells and the accumulation of MDSCs. CT-26 colon carcinoma cells (2 × 105) were injected s.c.

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

coTCRcys-transduced T cells control tumor growth in vivo.

Expression of versican G3 domain enhanced breast cancer cell mammosphere formation. Expression of versican G3 domain enhanced breast cancer cell mammosphere.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

Kinetic of NFAT-CBR expression.

Matriptase-2 inhibited breast tumor development in vivo.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

5FU-induced specific activation of CD8+ T cells.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Uptake of TEX by DCs in vivo.

GM-CSF is required for CA-MSC–induced tumor metastasis.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Tumor cell clusters with increased tumorigenesis, metastasis, and CD44 expression. Tumor cell clusters with increased tumorigenesis, metastasis, and CD44.

HMQ1611 inhibited breast tumor growth in mice.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

CD44 depletion blocks tumor cell aggregation and lung metastasis in vivo. CD44 depletion blocks tumor cell aggregation and lung metastasis in vivo. A,

In vivo bioluminescence imaging of primary tumors and tumor metastasis

Ex vivo imaging of lymph nodes with tumor metastasis using a bioluminescence imaging system. Ex vivo imaging of lymph nodes with tumor metastasis using.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

TAMs directly contribute to tumor hypoxia.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

The CCR5+ population of SUM-159 cells is enriched with tumor-initiating cells. The CCR5+ population of SUM-159 cells is enriched with tumor-initiating.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

A, VEGFR2 staining in the tumor rim and center.

The p53 Isoform Δ133p53β Promotes Cancer Stem Cell Potential

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Increased tumorigenic activities of TIM-3–expressing RCC cells.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

In vivo shRNA screening strategy.

Expression of anti-versican shRNA decreased breast cancer cell mammosphere and colony formation. Expression of anti-versican shRNA decreased breast cancer.

Presentation transcript:

Figure S1. Zhao et al. a b c Figure. S1. VEGF does not stimulate population increase and cell cycle changes in breast cancer cells. (a) cells from MDA-MB-231 were plated into 2D culture and treated +/- VEGF for 9 days. Cell number over time is plotted. (b) The cell cycle distributions of MDA- MB-231 and DT-22 cells treated +/- VEGF for 7 days. (c) Cell cycle distribution of MDA-MB- 231 cells dissociated from mammospheres formed +/- VEGF. All graphs show mean +/-SEM. % C VEGF MDA-MB-231 C VEGF DT-22 % C VEGF MDA-MB-231 spheres %

ab C VEGF BV+VEGF Day 0 1 Figure S2. Zhao et al. Figure. S2. VEGF exposure increases tumor cell survival/early establishment after tail vein injection and increases lung weights. (a) MDA-MB-231 cells were pre-treated +/- VEGF and +/- bevacizumab (BV+VEGF) for 7 days prior to tail vein injection. Photon flux on day 1 after injection is graphed as mean +/-SEMs plotted. (b) Representative IVIS images on day 0 and 1 post-injection. (c) Lungs from tumor bearing mice were removed and weighed at week 6 and graphed as mean weight +/- SEM. *p<0.05, **p<0.01. ** c * *

Figure. S3. Knock down of SOX2 does not change cell cycle. MDA-MB-231 cells were transfected with SiSOX2 and scramble control for 48 hours and cells were collected for cell cycle analysis. C SiSOX2 % Figure S3. Zhao et al.

C VEGF % Hop62 C VEGF % H23 a b Figure. S4. VEGF does not stimulate population increase and cell cycle changes in lung cancer cells. (a) A total of cells from Hop62 and H23 were plated into 2D culture and treated +/- VEGF for 9 days. Cell number over time is plotted. (b) The cell cycle distribution of Hop62 and H23 cells treated +/- VEGF for 7 days. All graphs show mean +/-SEM. Figure S4. Zhao et al.

Figure. S5. VEGF exposure fails to increase sphere formation in ER positive breast cancer cells. T47D and MDA-MB-361 cells were treated +/- VEGF for 7 days before mammosphere seeding +/- continued VEGF. All graphs show mean +/-SEM. Figure S5. Zhao et al. C VEGF Spheres C VEGF Spheres

Figure. S6. VEGF induces a potential autocrine loop. (a) MDA-MB-231 cells were treated +/- VEGF for 7 days and cells were collected form RT-PCR analysis of VEGF expression. (b) pVEGFR-2 levels were assayed in MDA-MB-231 cells treated +/- VEGF for 7 days or following removal of VEGF and recovery after a further 7 days. Graphs shows mean +/-SEM. (*p<0.05). Fold change * VEGF mRNA a VEGFR-2 pVEGFR-2 (Tyr1175) β-actin VEGF C VEGF withdraw b Figure S6. Zhao et al.